📅 PUBMED DAILY TRIAGE — 2026-10-31 Window: 2026-10-30T09:00:00Z → 2026-10-31T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: 100 | Candidates evaluated: 110 High priority: 4 | Standard: 33 | Low/archive: 0 | Unsolicited finds: 1 Run status: SUCCESS
🔴🟠 HIGH PRIORITY — Best Finds by Topic
Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)
PMID:42962270 · Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL. · 8/10 · CAR-T was associated with longer progression-free survival but greater first-year health-care contact burden than bispecific antibody therapy
CBC-based diagnostics and machine learning in hematology
No high-priority finds today (best retained candidate scored 0/10).
Early cancer detection (liquid biopsy, ctDNA, cfDNA)
PMID:42962916 · Development and multicenter validation of a cfDNA methylation-based PCR assay (myESCAP) with machine-learning prediction for non-invasive detection of esophageal cancer. · 9/10 · The assay achieved validation area under the curve near 0.82 with about 76 percent sensitivity and 89 percent specificity, although stage-one sensitivity remained limited PMID:42961485 · Machine Learning-Enhanced Terahertz-Colorimetric Dual-Mode Metadevice Based on Metallic Nanonetworks for microRNA Panel Assays. · 8/10 · The dual-mode assay reported diagnostic accuracy above 96 percent in both cohorts and detected all early pancreatic cancers in the small study
AI/ML in clinical diagnostics and imaging
PMID:42962916 · Development and multicenter validation of a cfDNA methylation-based PCR assay (myESCAP) with machine-learning prediction for non-invasive detection of esophageal cancer. · 9/10 · The assay achieved validation area under the curve near 0.82 with about 76 percent sensitivity and 89 percent specificity, although stage-one sensitivity remained limited PMID:42961485 · Machine Learning-Enhanced Terahertz-Colorimetric Dual-Mode Metadevice Based on Metallic Nanonetworks for microRNA Panel Assays. · 8/10 · The dual-mode assay reported diagnostic accuracy above 96 percent in both cohorts and detected all early pancreatic cancers in the small study
Precision oncology and genomic medicine
No high-priority finds today (best retained candidate scored 7/10).
Novel therapeutics: immunotherapy, CAR-T, targeted therapy
PMID:42962270 · Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL. · 8/10 · CAR-T was associated with longer progression-free survival but greater first-year health-care contact burden than bispecific antibody therapy
Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
PMID:42962687 · Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial. · 9/10 · At 72 weeks, each orforglipron dose produced substantially more clinically meaningful weight loss than placebo in the randomized trial
Aging, longevity, and population health
No high-priority finds today (best retained candidate scored 7/10).
Rare diseases with high unmet need
No high-priority finds today (best retained candidate scored 7/10).
🟢⚪ STANDARD (4-7) — Top by Topic
Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)
PMID:42961602 · Real-World Treatment Patterns and Outcomes of Zanubrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at University of California Academic Health Centers: A Retrospective Cohort Study. · 7/10 · Treatment Innovation PMID:42962272 · Plasma metabolomics and ctDNA analysis in newly diagnosed diffuse large B-cell lymphoma: an exploratory study. · 6/10 · Genomics/Precision Medicine PMID:42962268 · Therapeutic Synergy and Immune Activation by SUMOylation Pathway Inhibition in Acute Myeloid Leukemia. · 5/10 · Drug Development PMID:42962806 · Advances in Myeloproliferative Neoplasms by single-cell omics studies. · 5/10 · Genomics/Precision Medicine
CBC-based diagnostics and machine learning in hematology
No retained standard-priority articles.
Early cancer detection (liquid biopsy, ctDNA, cfDNA)
PMID:42962410 · Circulating tumor DNA-guided therapeutic strategies for metastatic colorectal cancer patients with multiple small pulmonary-limited nodules: A prospective cohort study. · 7/10 · Genomics/Precision Medicine PMID:42961770 · Multimodal Biosensing for Liquid Biopsy: A Critical Analysis of Signal Complementarity, Data Fusion, Artificial Intelligence, and Clinical Translation. · 5/10 · Diagnostics
AI/ML in clinical diagnostics and imaging
PMID:42962362 · Artificial intelligence-enabled detection of vascular perfusion defects on ventilation/perfusion (V/Q) scintigraphy for pulmonary embolism. · 7/10 · Diagnostics PMID:42963056 · Deep Learning-Assisted Diagnosis of Middle Ear Diseases in Otoendoscopy Across Clinician Experience Levels: Retrospective Reader Study. · 7/10 · Diagnostics PMID:42962244 · External validation and clinical implementation of clinical prediction models: a systematic review. · 6/10 · Diagnostics PMID:42962374 · An uncertainty-aware deep learning-based registration model for adaptive lung cancer radiotherapy. · 6/10 · Diagnostics PMID:42962674 · Subgroup deployment-readiness audit of calibration and clinical utility in perioperative infection prediction. · 6/10 · Diagnostics
Precision oncology and genomic medicine
PMID:42961623 · Differential detection of actionable alterations across CGP panels in biliary tract cancer: implications for panel selection. · 7/10 · Genomics/Precision Medicine PMID:42961883 · Cancer of Unknown Primary in Transition: From Empirical Chemotherapy to Immunotherapy and Molecularly Guided Treatment. · 6/10 · Genomics/Precision Medicine PMID:42962198 · Development of a NETs-Related Gene Signature in Pancreatic Cancer and Validation of SLC2A1's Potential in NETs Formation. · 5/10 · Genomics/Precision Medicine PMID:42962202 · Decoding Lung Cancer with Artificial Intelligence: A Path to Personalized Diagnostics and Therapy. · 5/10 · Genomics/Precision Medicine PMID:42962666 · Mitochondrial DNA abundance is a determinant of immunogenic cell death in cancer. · 5/10 · Drug Development
Novel therapeutics: immunotherapy, CAR-T, targeted therapy
PMID:42962928 · Intralesional cemiplimab for patients with early-stage cutaneous squamous cell carcinoma: Results from a dose-escalation study with expansion cohorts. · 7/10 · Treatment Innovation PMID:42963203 · DNA Immunotherapy (INO-3107) Long-Term Efficacy Supported by Enhanced Immunogenicity in HPV-6/11 RRP. · 7/10 · Treatment Innovation PMID:42962268 · Therapeutic Synergy and Immune Activation by SUMOylation Pathway Inhibition in Acute Myeloid Leukemia. · 5/10 · Drug Development PMID:42962829 · CLDN18.2-targeted CAR-NK cells suppress gastric cancer growth in preclinical models. · 5/10 · Drug Development PMID:42963013 · Repurposing the orphan drug nitisinone synergizes with sorafenib to sensitize immunotherapy-refractory MSS-CRC via metabolic stress-driven STING activation. · 5/10 · Drug Development
Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
PMID:42962309 · Urinary tract and genital infections with dapagliflozin and empagliflozin across type 2 diabetes, heart failure, and chronic kidney disease: An indication- and sex-stratified disproportionality analysis of eudravigilance reports. · 6/10 · Public Health PMID:42962450 · Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis. · 6/10 · Treatment Innovation PMID:42962748 · Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort. · 6/10 · Public Health PMID:42961949 · Sex-Specific Mechanisms and Therapeutics in Heart Failure: Translating Biology into Personalized Care. · 5/10 · Treatment Innovation PMID:42962407 · Incretin-based therapies in psychiatry: A landscape analysis of ongoing randomized trials registered on ClinicalTrials.gov. · 5/10 · Drug Development
Aging, longevity, and population health
PMID:42961715 · Nationwide trends and demographic projections of hospitalisations for vertebral fractures and postmenopausal osteoporosis in Germany: a 24-year registry-based study. · 7/10 · Public Health PMID:42961862 · Edentulism and functional disability in older adults: A longitudinal and cross-national study in England, the United States, and India. · 7/10 · Public Health PMID:42963183 · Changes in Long-Term Care Needs, Healthcare Costs, and Mortality Risk After Transcatheter Aortic Valve Implantation in Japan: The Longevity Improvement & Fair Evidence Study. · 7/10 · Public Health PMID:42961077 · Childhood hunger and cognitive impairment in later life among older adults in China: a nationwide case-control study using target maximum likelihood estimation. · 6/10 · Public Health PMID:42961293 · Life course and intrinsic ability in Brazilian adults and older adults: a mediation analysis. · 6/10 · Public Health
Rare diseases with high unmet need
PMID:42963107 · Long-Term Durability and Safety Signals of Systemic AAV Gene Therapy for Haemophilia A and B: A Systematic Review. · 7/10 · Treatment Innovation PMID:42963203 · DNA Immunotherapy (INO-3107) Long-Term Efficacy Supported by Enhanced Immunogenicity in HPV-6/11 RRP. · 7/10 · Treatment Innovation PMID:42961161 · Cryofibrinogenemia - an often-neglected rare disease: a case series. · 4/10 · Treatment Innovation
💡 UNSOLICITED FINDS
PMID:42961865 · Underdetected peripheral artery disease in people with hypertension: A narrative review of risk-stratified case-finding, diagnostic pathways, and equity in care. · 5/10 · The review proposes treatment-linked targeted testing while emphasizing that the complete pathway has not yet shown outcome benefit
📊 TODAY'S BREAKDOWN
- By research category: Treatment Innovation 9 | Early Detection 2 | Genomics/Precision Medicine 7 | Public Health 7 | Diagnostics 6 | Prevention 1 | Drug Development 5
- By evidence maturity: Validated 17 | Exploratory 20
- By watchlist topic:
- Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma): 13 reviewed / 5 kept / highest 8
- CBC-based diagnostics and machine learning in hematology: 0 reviewed / 0 kept / highest 0
- Early cancer detection (liquid biopsy, ctDNA, cfDNA): 10 reviewed / 4 kept / highest 9
- AI/ML in clinical diagnostics and imaging: 15 reviewed / 9 kept / highest 9
- Precision oncology and genomic medicine: 10 reviewed / 5 kept / highest 7
- Novel therapeutics: immunotherapy, CAR-T, targeted therapy: 15 reviewed / 6 kept / highest 8
- Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk: 15 reviewed / 6 kept / highest 9
- Aging, longevity, and population health: 12 reviewed / 5 kept / highest 7
- Rare diseases with high unmet need: 10 reviewed / 3 kept / highest 7
- Sentinel scan (unsolicited finds): 10 reviewed / 1 kept / highest 5
- By source type: peer_reviewed 37 | preprint 0
- Topics with zero HIGH articles: CBC-based diagnostics and machine learning in hematology; Precision oncology and genomic medicine; Aging, longevity, and population health; Rare diseases with high unmet need
🔧 RUN NOTES
- T2 primary and required fallback searches both returned zero results.
- The per-topic review cap remained 15; the sentinel cap remained 10.
- All 100 unique selected PMIDs were fetched and reviewed; endpoint coverage is complete.
- Oversized EFetch XML responses were recovered through individual text-mode EFetch calls.
- This rerun regenerates the complete daily corpus; duplicate Telegram alerts remain suppressed outside this output step.